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Summary
Background To rapidly reduce the burden of visceral leishmaniasis for national elimination programmes, an 
acceptable, safe, and eﬀ ective treatment is needed that can be delivered at primary health-care centres. We aimed to 
assess the tolerability, safety, and cure rate of single-dose liposomal amphotericin B (AmBisome, Gilead, USA) for 
visceral leishmaniasis treatment in such a setting in Bangladesh.
Methods We enrolled patients who had been diagnosed with visceral leishmaniasis at Muktagacha upazila 
(subdistrict) hospital, Bangladesh. Eligible participants were at least 5 years old and had a history of fever for more 
than 2 weeks, splenomegaly, rK39 rapid test positivity, and haemoglobin concentrations of at least 50 g/L. 
Participants were provided a one-oﬀ  intravenous infusion of liposomal amphotericin B (10 mg/kg bodyweight). 
Clinical assessments were done during treatment, before hospital discharge, and on days 30 and 180 after 
treatment. Cure was deﬁ ned as resolution of fever, decrease in spleen size, and an increase in haemoglobin by 
10% compared with baseline or to at least 100 g/L. We estimated eﬃ  cacy in terms of initial cure (at day 30) and 
ﬁ nal cure (at 6 months), and safety in all patients who were enrolled (intention-to-treat analysis). We also assessed 
eﬃ  cacy in all patients who completed treatment and 6 month follow-up after treatment with or without visceral 
leishmaniasis relapse (per protocol analysis). We assessed acceptability in terms of proportion of patients who 
consented to treatment. This study was registered with the Australian New Zealand Clinical Trial Registry, number 
CTRN12612000367842.
Findings Between March 5, and Aug 14, 2012, 329 (55%) of 594 cases of suspected visceral leishmaniasis were 
conﬁ rmed. Of these cases, ﬁ ve patients did not consent to treatment and 24 were ineligible for treatment. In the 
intention-to-treat analysis, 261 (87%) of 300 patients achieved initial cure and 290 (97%) achieved ﬁ nal cure. In the 
per-protocol analysis, 260 (88%) of 296 patients achieved initial cure and 289 (98%) achieved ﬁ nal cure. One patient 
did not start treatment owing to an allergic reaction to liposomal amphotericin B. During treatment or within 2 h 
afterwards, 79 (26%) patients developed fever, 109 (36%) had fever with rigor, and 56 (19%) had hypotension. No 
patients needed referral to a tertiary hospital for management of adverse events.
Interpretation Treatment of visceral leishmaniasis in a primary health-care facility with single-dose liposomal 
amphotericin B could safely and eﬀ ectively be adopted by the national visceral leishmaniasis elimination programme 
in Bangladesh.
Funding Neglected Tropical Diseases (WHO), Agencia Española de Cooperación Internacional.
Introduction
Visceral leishmaniasis is potentially fatal, and causes 
substantial morbidity in 200 000–400 000 individuals 
every year, of whom 90% live in the Indian subcontinent. 
Visceral leishmaniasis causes extreme suﬀ ering and 
ﬁ nancial loss in the poorest populations, who mostly live 
in remote rural areas. The greatest burden falls on India, 
with more than 100 000 new cases every year, and 
Bangladesh, with an estimated 12 440–24 900 new cases 
per year.1
In 2005, the Governments of Bangladesh, India, and 
Nepal committed to eliminate visceral leishmaniasis by 
2015.2 The elimination strategy included the prompt 
treatment of cases with oral miltefosine. This drug was 
the only realistic option at the time, despite its potential 
teratogenicity, risk of non-compliance, and propensity 
for development of resistant strains.3 However, after 
rollout, miltefosine showed an eﬀ ectiveness of only 83% 
in a phase 4 trial in Bangladesh, and in Nepal 20% of 
study participants relapsed after 12 months with a ﬁ nal 
cure rate of only 79%.4,5 These limitations, and the 
restrictions in the use of miltefosine (it is contraindicated 
in pregnancy and caution must be taken in women of 
childbearing age), restricts its use in large-scale 
programmes.
Short-course combination therapy regimens as 
alternatives to miltefosine—including liposomal 
amphotericin B plus miltefosine, paromomycin, or 
miltefosine plus paromomycin—showed promising 
results in a phase 3 trial in India, but the results of the 
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implementation studies at the primary health-care level 
will only be available in 2015.6,7 The only other option is 
liposomal amphotericin B (AmBisome, Gilead, USA), 
which has been shown to be very eﬀ ective and safe for 
treatment of visceral leishmaniasis.8 Previously, the 
liposomal form was prohibitively expensive for use in 
control programmes, but, in 2007, Gilead announced a 
price reduction of 90% (US$18 per 50 mg vial) for all low-
income and middle-income countries in which visceral 
leishmaniasis is endemic. The reduction in price opened 
up the possibility of use of liposomal amphotericin B in 
these resource-poor settings. A phase 3 study9 in India 
showed an eﬃ  cacy of 95·7% with a single-dose regimen 
of liposomal amphotericin B at a dose of 10 mg/kg, with 
only minor side-eﬀ ects. However, this study did not 
report rates of hypersensitivity. This result led to the 
recent recommendation of the WHO Expert Committee 
on the Control of Leishmaniasis to use liposomal 
amphotericin B as a ﬁ rst-line treatment for visceral 
leishmaniasis in the Indian subcontinent.10
Immediate rollout of an eﬀ ective and safe short-course 
treatment regimen is essential for the attack phase of the 
visceral leishmaniasis elimination programme, which 
aims to reduce the incidence to less than one case per 
10 000 population at risk.11 A single-dose liposomal 
amphotericin B regimen, which is very eﬀ ective, safe, 
and is likely to have fewer issues of poor compliance 
because of its lower side-eﬀ ect proﬁ le, is in principle an 
ideal alternative to miltefosine. However, distribution of 
liposomal amphotericin B requires a cool chain, which 
might be an impediment to its implementation in 
remote regions where most of the visceral leishmaniasis 
patients seek care. Therefore, studies into the feasibility 
of the use of liposomal amphotericin B in rural public 
hospitals are needed.
In this study, we aimed to assess the eﬀ ectiveness, 
safety, and feasibility of a 10 mg/kg single-dose liposomal 
amphotericin B regimen in a rural public hospital in 
Bangladesh. Results will not only serve the national 
visceral leishmaniasis control programme of Bangladesh, 
but will also allow the regional elimination programme 
to make an informed decision on changing its large-scale 
treatment strategy.
Methods
Study design and participants
The study was done in the Muktagacha upazila hospital 
(subdistrict hospital) of the district of Mymensingh, 
which is one of the areas of Bangladesh where visceral 
leishmaniasis is most endemic. We enrolled participants 
of either sex, who were aged at least 5 years, and had a 
history of fever for more than 2 weeks, splenomegaly, 
rK39 rapid test positivity, and haemoglobin concen-
trations of at least 50 g/L.
We excluded participants with a history of intercurrent 
or presence of clinical signs or symptoms of uncontrolled 
concurrent diseases or conditions before start of study 
treatment, any condition that might prevent the patient 
from completing the study therapy and subsequent 
follow-up (investigator assessed), a history of allergy or 
hypersensitivity to amphotericin B, previous treatment 
for visceral leishmaniasis within 2 months of enrolment, 
previous treatment failure with amphotericin B, 
post-kala-azar dermal leishmaniasis, and pregnant 
women.  We excluded pregnant women from this study 
because present evidence about safety of liposomal 
amphotercin B during pregnancy is limited. Furthermore, 
visceral leishmaniasis during pregnancy needs to be 
managed in the tertiary hospital even with liposomal 
amphotericin B. Only participants who provided 
informed written consent to participate in the study were 
enrolled. The study was approved by the International 
Centre for Diarrhoeal Disease Research, Bangladesh 
(icddr,b), and WHO’s ethics committee.
Procedures
Before study start, two training sessions in management 
of liposomal amphotericin B and treatment of patients 
with visceral leishmaniasis with liposomal amphotericin B 
were given to the hospital staﬀ  of Muktagacha (by SS). 
Refresher training was provided by DM.
At enrolment, we took a complete medical history, did a 
physical examination, and measured bodyweight (with a 
Salter scale 465; Salter, Australia), height (with a locally 
made height scale), and haemoglobin concentrations 
(with the HemoCue system; HemoCue, Kuvettgatan, 
Sweden), and did a second rK39 test (with kala-azar 
detect; InBios, Seattle, WA, USA). We did a urine-based 
test for pregnancy for female patients of childbearing age.
All participants were admitted to the kala-azar ward of 
Muktagacha hospital for 1 night and followed up during 
this time by the hospital’s doctor and nurse. All 
participants received paracetamol (500 mg for adults and 
10 mg/kg for children younger than 12 years) and 
chlorphenamine (4 mg for adults and 1–2 mg for children 
younger than 12 years). We tested for potential allergies to 
study drug before the main infusion, consisting of 1 mg 
of liposomal amphotericin B diluted in 12·5 mL of 
dextrose 5% in water and administered for about 
15–20 min.
Participants who did not show any allergic reaction 
during the allergic test received a dose of 10 mg/kg of 
liposomal amphotericin B. The intravenous infusion was 
administered over 2 h. Vital parameters were taken 
before trial medication, every 30 min during the drug 
infusion, 2 h and 24 h after treatment, and before 
discharging of the patient. We measured haemoglobin 
concentrations before treatment, before discharge from 
hospital, on day 30, and on day 180 after treatment.
After completion of physical examinations, participants 
were discharged from the hospital about 24 h after the 
infusion. Patients were requested to return for a follow-
up visit at 30 days and 180 days after treatment. They 
were also instructed to visit the hospital if they did not 
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feel well at any time during follow-up. At the follow-up 
visits, patients underwent full clinical examination and 
had a haemoglobin concentration test. Patients with 
suspected treatment failure or relapse of visceral 
leishmaniasis were referred to Muktagacha hospital 
where, after clinical assessment by the hospital doctors, 
Figure: Study proﬁ le
*Patient with bradycardia received partial treatment.
594 patients with suspected visceral leishmaniasis assessed
329 diagnosed with visceral leishmaniasis  by hospital doctors 
 according to national guidelines and oﬀered study treatment  
324 patients or guardians agreed to participate
300 enrolled
265 rK39 negative
5 did not consent to treatment
298 assessed for initial cure at day 30
290 had ﬁnal cure (289 fully treated, 1 partly treated)
1 died on treatment day 8 (not regarded as treatment-related)
24 not enrolled
 4 rK39 negative
 7 no splenomegaly
 1 pregnancy
 2 pneumonia
 8 concurrent disease
 2 severe anaemia
298 received complete treatment
 1 received partial treatment*
3 suspected 
  treatment failures  
  (2 conﬁrmed)
1 had thalassaemia
260 fully treated and 1 partly treated had initial cure
1 did not receive study drug after allergic reaction to allergen test
1 discontinued study drug after 6·6 mg/kg dose because of 
  development of bradycardia
36 fully treated improved clinically, improving 
  resolution of fever and decrease in spleen size, 
  but did not fulﬁl the haemoglobin criteria
3 treatment failures 1 treatment failure
258 fully treated and 1 partly treated were assessed 
  for ﬁnal cure at 180 days
35 assessed for ﬁnal cure at 180 days
1 did not improve clinically and was referred for 
  suspected treatment failure (conﬁrmed 
  parasitologically)
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they were referred to a specialised visceral leishmaniasis 
hospital (Surja Kanta Kala-azar Reseach Centre) of 
Mymensingh Medicial College Hospital for 
parasitological conﬁ rmation and management. Patients 
who were referred to the specialised centre because of 
initial failure of treatment as deﬁ ned by study criteria, 
but did not require rescue treatment following their 
assessment by visceral leishmaniasis experts, were also 
followed up for ﬁ nal cure.
At day 30 after treatment we assessed rates of initial cure, 
which was deﬁ ned as resolution of fever, decrease in 
spleen size, and an increase in haemoglobin concentration 
by 10% compared with baseline or to at least 100 g/L. 
Participants who were deemed to have initial cure, were 
followed up for 6 months for assessment of ﬁ nal cure, 
deﬁ ned as the absence of relapses after day 30, decrease in 
spleen size compared with day 30, and increase of 
haemoglobin by 10% compared with day 30 or to at least 
100 g/L. Treatment failure was assumed if a patient did not 
achieve initial cure and had Leishmania donovani 
amastigotes in their spleen aspirate. A patient with initial 
cure, but with reappearance of visceral leishmaniasis 
symptoms during follow-up and L donovani bodies in their 
spleen aspirate was deﬁ ned as a case of visceral 
leishmaniasis relapse. All participants with parasitologically 
conﬁ rmed treatment failure or relapse received rescue 
treatment with liposomal amphotercin B at total dose of 
15 mg/kg bodyweight (three injections of 5 mg/kg each 
over 3 days) in the specialist centre in Mymensingh.
Statistical analysis
The main objective of this study was to obtain data for 
feasibility of use of single-dose liposomal amphotericin B 
at the peripheral level close to the endemic villages. 
A purposive sample size was determined, assuming that 
at least 85% of patients with visceral leishmaniasis who 
attended the hospital were eligible to be treated with 
single-dose liposomal amphotericin B, and aiming to 
obtain at least 95% cure rate at 6 months and with up to 
3% of treated patients developing drug-related adverse 
events requiring referral to a tertiary hospital for 
management. Data are expressed as mean values. We 
calculated cure rates in the intention-to-treat population 
(all patients who received at least one dose of study drug) 
and per-protocol population (patients who received 
complete dose of 10 mg/kg and were followed up for 
Children aged <18 years 
(n=175)
Adults aged ≥18 years 
(n=125)
Overall (n=300)
Age, years
Mean (SD) 9·4 (3·1) 32·5 (10·9) 19 (13·61)
Median (IQR) 9 (7–11) 30 (22·5–42) 13 (8–27)
Sex
Female 68 (39%) 43 (34%) 111 (37%)
Male 107 (61%) 82 (66%) 189 (63%)
Primary visceral leishmaniasis 132 (75%) 100 (80%) 232 (77%)
Previous treatment for visceral leishmaniasis 43 (25%) 25 (20%) 68 (23%)
Miltefosine monotherapy 34 (19%) 12 (10%) 46 (15%)
Paromomycin monotherapy 1 (1%) 5 (4%) 6 (2%)
Sodium stibogluconate 4 (2%) 6 (5%) 10 (3%)
Multidose liposomal amphotericin B 4 (2%) 2 (2%) 6 (2%)
Mean patient-reported duration of fever, days 68·1 (38·2) 63·4 (39·8) 66·2 (38·9)
Spleen size at enrolment, cm
Mean (SD) 6·9 (3·7) 6·4 (3·7) 6·6 (3·7)
≤5 82 (47%) 46 (37%) 128 (43%)
5–<10 74 (42%) 59 (47%) 133 (44%)
≥10 19 (11%) 20 (16%) 39 (13%)
Mean (SD) bodyweight at baseline, kg 22·4 (9·7) 44·0 (6·8) 31·4 (13·7)
Mean (SD) BMI at baseline, kg/m² 13·7 (1·8) 17·5 (2·0) 15·3 (2·6)
Underweight* 126 (72%) 92 (74%) 218 (73%)
Systolic/diastolic blood pressure, mm Hg 100/65 (80/50–120/90) 104/67 (80/50–120/90) 102/66 (80/50–120/90)
Pulse rate, beats per min 97·4 (66–128) 85·5 (60–120) 92·4 (60–128)
Respiratory rate, breaths per min 24·1 (16–40) 21·7 (16–32) 23·1 (16–40)
Body temperature, °C 37·0 (35·5–39·9) 37·0 (36–40) 37·0 (35·5–40·0)
Haemoglobin, g/L 9·3 (5·1–14·4) 9·9 (5·1–16·4) 9·6 (5·1–16·4)
Data are n (%) or mean (range), unless otherwise stated. BMI=body-mass index. *BMI during enrolment of <18·5 kg/m² for adults and BMI <5th percentile for children 
according to the US Centers for Disease Control and Prevention BMI Percentile Calculator for Children and Teens.
Table 1: Baseline characteristics
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6 months after treatment). Safety analysis included 
calculation of incidence of all adverse events. We 
compared cure rates between diﬀ erent age groups and 
with disease types (primary vs relapse)  with the χ² test 
and Yate’s correction where applicable. We regarded 
p≤0·05 as signiﬁ cant.
This study was registered with the Australian New 
Zealand Clinical Trial Registry, number 
CTRN12612000367842.
Role of funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
We enrolled 300 participants between March 5 and 
Aug 14, 2012, and 6 month follow-up was completed by 
Feb 14, 2013 (ﬁ gure, table 1). Notably, 232 (77%) of 
participants had primary visceral leishmaniasis and 
68 (23%) were relapses. 46 (68%) of these patients with 
relapse had previously received miltefosine. In general, 
study patients were underweight and young (table 1). 
175 (58%) patients had anaemia, deﬁ ned as a haemoglobin 
concentration of less than 100 g/L.
One adult developed hypotension during the allergy 
test with 1 mg amphotericin B and did not begin 
treatment because of concern over hypertensive shock, 
and was treated with oral miltefosine. Study drug 
infusion was stopped in another participant after 1 h 
because of prolonged bradycardia. These problems were 
locally managed and reverted without consequences. 
Thus 298 participants completed the full treatment, and 
one patient had completed partial treatment. Mean dose 
of amphotericin B was 313·87 mg (range 110–660), with a 
mean volume of amphotericin B of 78·47 mL 
(27·50–165·0) and diluents of 234·40 mL (82·5–495·0). 
One male patient aged 39 years died on day 8 after 
treatment because of an exacerbation of a pre-existing 
chronic obstructive pulmonary problem that was not 
related to the study drug. Therefore, 298 participants 
were available for assessment of initial cure at day 30.
Table 2 shows initial cure rates in the intention-to-treat 
and per-protocol populations. One participant did not 
show any clinical improvement and was referred to the 
specialist centre, where a spleen aspiration conﬁ rmed 
the presence of leishmania parasites. The remaining 
36 participants who were not regarded as initially cured 
according to the study protocol had not reached the 
necessary increase in haemoglobin concentrations by 
10% compared with baseline value. However, these 
36 participants had no clinical evidence of active diseases. 
In all these patients, spleen sizes had decreased in size 
and no recurrence of fever was noted. Nevertheless, we 
referred them to the hospital doctor. On the basis of 
hospital doctor’s judgment, they were not referred to the 
specialist hospital, but were followed up closely and their 
haemoglobin concentration was assessed on day 60 or 
day 90. In all cases apart from one, the haemoglobin 
concentration increased to more than 100 g/L at day 60 or 
day 90, and therefore these patients were asked to return 
for ﬁ nal cure assessment. One patient was diagnosed 
with thalassaemia at the specialist centre (ﬁ gure).
No participants were lost during the follow-up period. 
Between day 30 and day 180 assessment, seven 
participants relapsed, resulting in a per-protocol ﬁ nal 
cure rate at 6 months of 98% and an intention-to-treat 
cure rate of 97% (table 2).
Most patients tolerated single-dose liposomal 
amphotericin B (table 3). All drug-related adverse events 
were mild-to-moderate and all were managed with the 
resources available at the Mugtagasha upazila hospital. 
None of the participants required referral to tertiary 
hospital for complications. The most common adverse 
event during trial medication was fever, vomiting, and 
fever with rigor (table 3). Within 2 h of medication, the 
most common adverse event was fever with rigor 
followed by fever and hypotension (table 3), which 
responded well to oral rehydration therapy only. On the 
day after infusion, all patients were afebrile and all 
adverse events had resolved.
We noted a reduction in haemoglobin concentrations 
of 2·00–2·75 g/L in six (2%) of 299 participants, without 
Intention-to-treat analysis Per-protocol analysis*
n/N (%) Diﬀ erence 
(95% CI; p value)
n/N (%) Diﬀ erence 
(95% CI; p value)
Initial cure
By age group 9·3% (1·2–17·3; 
0·075) 
8·6%(1·0–16·5; 
0·041)
Children 159/175 (91%) 159/174 (91%)
Adult 102†/125 (82%) 101/122 (83%)
By visceral leishmaniasis type 9·2% (2·0–16·5; 
0·075)
8·0% (1·0–15·2; 
0·121)
Primary 197†/232 (85%) 197/229 (86%)
Relapse 64/68 (94%) 63/67 (94%)
Overall 261†/300 (87%) 260/296 (88%)
Final cure
By age group 1·6% (–2·4–5·6; 
0·664)
2·6% (–1·5–5·7; 
0·282)
Children 168/175 (96%) 168/174 (97%)
Adult 122†/125 (98%) 121/122 (99%)
By visceral leishmaniasis type 4·3% (1·7–6·9; 
0·175)
3·1% (1·0–5·3; 
0·322)
Primary 222†/232 (96%) 222/229 (97%)
Relapse 68/68 (100%) 67/67 (100%)
Overall 290†/300 (97%) 289/296 (98%)
 *Four patients were excluded; one patient was lost to follow-up because of a serious adverse events not regarded as 
related to study drug; one patient had a partial treatment; one patient was misdiagnosed; and one patient was 
hypersensitive to amphotericin B. †One patient with partial treatment achieved initial and ﬁ nal cure.
Table 2: Eﬃ  cacy of single-dose liposomal amphotericin B for visceral leishmaniasis
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any clinical signs or symptoms associated with the 
reduction. Four female participants became pregnant 
within months after treatment and in one the pregnancy 
was completed with delivery of a term normal birth after 
6 months of follow-up. The other three pregnant women 
were clinically healthy during the last follow-up visit.
Discussion
In view of present treatment options, WHO has 
recommended monotherapy with liposomal 
amphotericin B during the attack phase of visceral 
leishmaniasis elimination to rapidly reduce the burden of 
the disease.8,11 Therefore, our study provides an important 
assessment of the feasibility of administering single-dose 
liposomal amphotericin B close to endemic villages at a 
rural hospital primary health-care level (panel). Our study 
showed that treatment of visceral leishmaniasis was 
feasible in a rural hospital in Bangladesh with a single 
intravenous infusion of liposomal amphotericin B. Most 
patients were treated in the rural hospital only (91%), with 
a high acceptance (98%), cure rate (97% in the intention-
to-treat analysis), and good safety proﬁ le. We noted no 
serious adverse events related to study drug and all 
adverse events were manageable in the hospital with 
straightforward procedures. Thus, we believe single-dose 
liposomal amphotericin B oﬀ ers the best option in terms 
of eﬃ  cacy and compliance during the attack phase of the 
visceral leishmaniasis elimination programme and this 
strategy could be extended to Bangladesh, India, and 
Nepal.
Furthermore, a study in the ﬁ ve most visceral 
leishmaniasis endemic upazilas (subdistricts) in 
Mymensingh district noted that implementation of one-
oﬀ  intravenous infusion of liposomal amphotericin B 
was technically and operationally feasible (Eva-Maria 
Maintz [Freiburg University, Freiburg, Germany]; 
unpublished data). In that study, most of the consumables 
needed for drug preparation and administration were 
available, all hospitals were equipped with a generator for 
periods when the central electricity supply was cut due to 
loading issues, and most paramedic staﬀ  were familiar 
with intravenous infusion. The study noted that training 
was needed, but, as our study shows, this training was 
feasible in the Muktagacha district.
Before the start of the study, we expected referral of up 
to 3% visceral leishmaniasis cases to the tertiary hospital 
for management of eventual complications. However, no 
referral was necessary because all adverse events were 
mild. Incidence of adverse events was about 47% during 
treatment and 63% within 2 h after treatment and in all 
cases were manageable with simple intervention 
including oral rehydration solution for hypotension or 
vomiting and antipyretics for fever and rigor. 
Furthermore, four pregnancies occurred after of 
treatment during the follow-up period. Pagliano and 
colleagues noted in their observational study12 that 
liposomal amphotericin B for visceral leishmaniasis 
during pregnancy was safe and eﬀ ective for mother and 
fetus. Firm conclusions about safety and eﬃ  cacy during 
pregnancy and for the fetus cannot be made on the basis 
Events during treatment Events within 2 h after treatment
Fever 36 (12%) 43 (14%)
Fever with rigor 22 (7%) 87 (29%)
Hypotension 19 (6%) 37 (12%)
Hypothermia 4 (1%) 9 (3%)
Nausea 4 (1%) 4 (1%)
Vomiting 32 (11%) 3 (1%)
One time 27 (9%) 1 (<1%)
Two times 2 (1%) 1 (<1%)
Three times 3 (1%) 0
Four times 0 1 (<1%)
Headache 7 (2%) 2 (1%)
Epigastria, abdominal pain, or 
abdominal discomfort
3 (1%) 0
Mild skin allergic rash* 3 (1%) 0
Back pain 1 (<1%) 1 (<1%)
Neck ache 1 (<1%) 0
Body ache 2 (1%) 0
Bradycardia† 1 (<1%) 0
Diarrhoea 0 2 (1%)
Restlessness 1 (<1%) 0
*Managed by antihistamines (in three patients) and hydrocortisone treatment (in one patient). †Managed with 
0·6 mg intramuscular atropine.
Table 3: Safety proﬁ le for all 300 enrolled patients
 Panel: Research in context
Systematic review
In 2010, the WHO Expert Advisory panel on leishmaniasis recommended intravenous single 
infusion with liposomal amphotericin B (10 mg/kg bodyweight) for treatment of visceral 
leishmaniasis in the Indian subcontinent to quickly reduce cases of the disease. To investigate 
the basis of this recommendation, we searched PubMed for articles published in English with 
the search terms “visceral leishmaniasis”, “treatment”, “liposomal amphotericin B”, and 
“single dose”. We identiﬁ ed four randomised controlled trials with single doses of liposomal 
amphotericin B, ranging from 5 mg/kg to 15 mg/kg doses. Three of these four studies were 
done in India by one group. The only study with a 10 mg/kg single dose was fairly small. 
These studies showed a high eﬃ  cacy and safety proﬁ le when given to patients with visceral 
leishmaniasis in controlled conditions. However, little information existed about the 
feasibility, acceptability, cure rates, and safety proﬁ le of single-dose liposomal amphotericin 
B for visceral leishmaniasis if given in uncontrolled condition such as in a rural primary care 
hospital (where most of the cases with visceral leishmaniasis seek medical care). 
Interpretation
The feasibility of single-dose liposomal amphotericin B we noted at the community level 
will help inform policy makers. On the basis of our study and previous trials, single-dose 
liposomal amphotericin B should be the front-line treatment for visceral leishmaniasis in 
Bangladesh and neighbouring countries. The clinical implications are important, because 
patients can now be diagnosed and cured of visceral leishmaniasis in 1 day in a rural 
hospital setting, which will greatly improve compliance, and with high eﬃ  cacy and low 
adverse events. Amphotericin B could therefore support the elimination of visceral 
leishmaniasis as a major public health problem in southeast Asia.
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of our study, but our ﬁ ndings are encouraging and a 
long-term follow-up is planned.
Despite the good safety proﬁ le we noted, some concerns 
emerged. One patient (<1%) had hypersensitivity to lipo-
somal amphotericin B. Thus, the allergic test needs to be 
done as recommended by the manufacturer (ie, allergic 
test with 1 mg liposomal amphotericin B) and should not 
be done with the prepared solution for intravenous 
infusion. This strategy will help to avoid wastage and will 
ease management of the patient if they are allergic to the 
drug. In another patient (<1%), treatment had to be 
interrupted because of development of bradycardia. We 
noted haemoglobin reductions in six treated patients 
(2%), warranting close follow-up of patients during 
treatment and within 24 h after treatment for eventual 
drug-related cardiac toxicity and potential cardiac failure 
from signiﬁ cant reductions of haemoglobin concentration.
56 (19%) patients with visceral leishmaniasis were 
hypotensive. Medical staﬀ  should therefore be prepared 
for its management before the start of treatment. 
Haemoglobin concentrations were a good indicator of cure 
and concentrations did not reach normal for more than a 
month in a small proportion of participants. However, our 
study showed that low initial haemoglobin concentrations 
are not associated with a failure of treatment.
A potential question for implementation of liposomal 
amphotericin B is the risk of resistance. However, when 
used as a single dose, the risk of resistance is very low. 
Lachaud and colleagues showed no emergence of 
leishmania resistance to liposomal amphotericin B even 
after repeated multidose treatments or single-dose 
prophylaxis use in immunosuppressed patients with 
visceral leishmaniasis.13 Also, no guarantee exists that any 
treatment combination is safe from resistance: resistance 
to combinations can be selected for in vitro over long 
periods.14,15 We suggest that combination therapies could 
be considered once the elimination target has been 
reached with single-dose liposomal amphotericin B.
Overall, treatment of visceral leishmaniasis with single-
dose liposomal amphotericin B in a rural hospital in 
Bangladesh was feasible, acceptable, safe, and eﬃ  cacious. 
The present recommendation of WHO for its use as a 
ﬁ rst-line drug for visceral leishmaniasis in southeast 
Asia is supported by these results. The national visceral 
leishmaniasis elimination programme in Bangladesh 
should consider its implementation in practice and such 
a strategy could represent an example for India and 
Nepal, especially when combined with active case 
detection and vector control.
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